What is a stock summary page? Click here for an overview.
Business Description
Arcus Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US03969F1093
Description
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.3 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | -0.22 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -0.26 | |||||
| Beneish M-Score | -2.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -17.9 | |||||
| 3-Year FCF Growth Rate | 20 | |||||
| 3-Year Book Growth Rate | -23.8 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.42 | |||||
| 9-Day RSI | 36.68 | |||||
| 14-Day RSI | 35.54 | |||||
| 3-1 Month Momentum % | -36.14 | |||||
| 6-1 Month Momentum % | -34.87 | |||||
| 12-1 Month Momentum % | -38.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | |||||
| Quick Ratio | 4.5 | |||||
| Cash Ratio | 4.33 | |||||
| Days Sales Outstanding | 38.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.2 | |||||
| Shareholder Yield % | -26.27 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -120.16 | |||||
| Net Margin % | -109.69 | |||||
| FCF Margin % | -68.22 | |||||
| ROE % | -49.58 | |||||
| ROA % | -23.68 | |||||
| ROIC % | -102.88 | |||||
| 3-Year ROIIC % | 46.32 | |||||
| ROC (Joel Greenblatt) % | -567.07 | |||||
| ROCE % | -28.19 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.1 | |||||
| PB Ratio | 1.73 | |||||
| Price-to-Tangible-Book | 1.73 | |||||
| EV-to-EBIT | -0.1 | |||||
| EV-to-Forward-EBIT | -0.06 | |||||
| EV-to-EBITDA | -0.1 | |||||
| EV-to-Revenue | 0.11 | |||||
| EV-to-Forward-Revenue | 0.17 | |||||
| EV-to-FCF | -0.24 | |||||
| Price-to-GF-Value | 0.56 | |||||
| Price-to-Net-Current-Asset-Value | 2.39 | |||||
| Price-to-Net-Cash | 2.69 | |||||
| Earnings Yield (Greenblatt) % | -1000 | |||||
| FCF Yield % | -18.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:RCUS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Arcus Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 258 | ||
| EPS (TTM) ($) | -3.1 | ||
| Beta | 0.93 | ||
| 3-Year Sharpe Ratio | -0.5 | ||
| 3-Year Sortino Ratio | -0.69 | ||
| Volatility % | 29.37 | ||
| 14-Day RSI | 35.54 | ||
| 14-Day ATR ($) | 0.577381 | ||
| 20-Day SMA ($) | 9.65 | ||
| 12-1 Month Momentum % | -38.16 | ||
| 52-Week Range ($) | 8.82 - 19.11 | ||
| Shares Outstanding (Mil) | 105.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arcus Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arcus Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Arcus Biosciences Inc Frequently Asked Questions
What is Arcus Biosciences Inc(RCUS)'s stock price today?
The current price of RCUS is $9.12. The 52 week high of RCUS is $19.11 and 52 week low is $8.82.
When is next earnings date of Arcus Biosciences Inc(RCUS)?
The next earnings date of Arcus Biosciences Inc(RCUS) is 2025-05-08 Est..
Does Arcus Biosciences Inc(RCUS) pay dividends? If so, how much?
Arcus Biosciences Inc(RCUS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers